Literature DB >> 1986176

Estimating the treatment costs of breast and lung cancer.

M S Baker1, L G Kessler, N Urban, R C Smucker.   

Abstract

The Continuous Medicare History Sample File (CMHSF) was used to derive an estimate of the lifetime direct medical expenses attributable to two chronic diseases, lung cancer and female breast cancer. These two cancers are the leading cancer causes of death in men and women in the United States. They inflict large costs on the population, both direct and indirect, but the costs have been difficult to measure. The primary obstacle to quantification is the intermittent and long-term nature of treatment for these diseases. A complete record of expenses cannot usually be obtained from one source, however, a review of all the national health surveys, as well as the Medicare statistical files identified the CMHSF, which is maintained by the Health Care Financing Administration in a format suitable for calculation of cumulative medical expenses. Some of the pertinent features of the CMHSF include the following: 1) it is a nationally representative sample of the Medicare population, 2) it is longitudinal covering an 8-year period from 1974 to 1981, 3) it captures the majority of medical expenses for each enrollee, and 4) it can be linked to other national data bases such as the National Death Index. Charges for three phases of cancer treatment were derived from the file: initial therapy, maintenance care, and terminal care. A method is described for computing the present value of life-time treatment costs from the phase-specific charges. The lifetime cost of treating breast cancer in 1984 dollars is $36,926 and lung cancer is $12,510.

Entities:  

Mesh:

Year:  1991        PMID: 1986176     DOI: 10.1097/00005650-199101000-00004

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  48 in total

Review 1.  Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.

Authors:  K L Goa; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

Review 2.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

Review 3.  Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.

Authors:  B E Hillner; T J Smith; C E Desch
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

4.  Effect of marital status on treatment and survival of extremity soft tissue sarcoma.

Authors:  V K Alamanda; Y Song; G E Holt
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

5.  Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.

Authors:  M Nuijten; L Meester; F Waibel; S Wait
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

Review 6.  Breast cancer management: quality-of-life and cost considerations.

Authors:  Davide Radice; Alberto Redaelli
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Clinical surveillance for early stage breast cancer: an analysis of claims data.

Authors:  M S Simon; M Stano; R K Severson; M S Hoff; D W Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Lifetime costs of the top five cancers in Taiwan.

Authors:  Hui-Chu Lang; Shi-Liang Wu
Journal:  Eur J Health Econ       Date:  2011-03-27

Review 9.  Efficacy and economics of hormonal therapies for advanced breast cancer.

Authors:  Michael S Simon; Dina Ibrahim; Lisa Newman; Miron Stano
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  The costs of treating breast cancer in the US: a synthesis of published evidence.

Authors:  Jonathan D Campbell; Scott D Ramsey
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.